Bioventus Inc.
For the period ended Sep 27, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 27, 2025 · Filed Nov 4, 2025
BVS$11.18+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Condensed Statements of Cash Flows for the
Consolidated Condensed Statements of Cash Flows
Nine Months Ended September 27, 2025 and September 28, 2024
(Amounts in thousands)
| Nine Months Ended | ||
|---|---|---|
| September 27, 2025 | September 28, 2024 | |
| Operating activities: | ||
| Net income (loss) | $9,956 | $(46,446) |
| Adjustments to reconcile net loss to net cash from operating activities: | ||
| Depreciation and amortization | 35,317 | 37,150 |
| Provision (benefit) for credit losses | 944 | (613) |
| Equity-based compensation | 9,233 | 11,258 |
| Change in fair value of contingent consideration | — | 1,078 |
| Impairment of assets | — | 33,901 |
| Loss on extinguishment | 326 | — |
| Loss on disposals | 81 | — |
| Deferred income taxes | 222 | (8,609) |
| Unrealized gain on foreign currency fluctuations | (333) | (133) |
| Other, net | 1,006 | 1,559 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (2,801) | (4,874) |
| Inventories | (4,399) | (10,874) |
| Accounts payable and accrued expenses | (15,370) | 1,224 |
| Other current and noncurrent assets and liabilities | 2,523 | 4,852 |
| Net cash from operating activities | 36,705 | 19,473 |
| Investing activities: | ||
| Settlement from the sale of a business | (686) | — |
| Purchase of property and equipment | (1,982) | (432) |
| Investments and acquisition of distribution rights | — | (709) |
| Net cash from investing activities | (2,668) | (1,141) |
| Financing activities: | ||
| Proceeds from issuance of Class A common stock | 1,563 | 1,339 |
| Tax withholdings on equity-based compensation | (9) | — |
| Payment of contingent consideration | (19,771) | — |
| Borrowing on revolver | 45,000 | — |
| Payment on revolver | (20,000) | — |
| Proceeds from the issuance of long-term debt, net of discount | 31,907 | — |
| Payments on the extinguishment of long-term debt | (65,765) | — |
| Debt refinancing costs | (697) | (1,180) |
| Scheduled payments on long-term debt | (5,302) | (11,320) |
| Other, net | (619) | (564) |
| Net cash from financing activities | (33,693) | (11,725) |
| Effect of exchange rate changes on cash | 238 | (497) |
| Net change in cash and cash equivalents | 582 | 6,110 |
| Cash and cash equivalents at the beginning of the period | 41,582 | 36,964 |
| Cash and cash equivalents at the end of the period | $42,164 | $43,074 |
| Supplemental disclosure of noncash investing and financing activities | ||
| Accounts payable for purchase of property, plant and equipment | $218 | $113 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.